DTP Vaccines Market Report 2025

The DTP vaccines market size has grown strongly in recent years. It will grow from $5.17 billion in 2024 to $5.47 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increase in healthcare access, continuous protection towards infectious diseases and rising awareness of immunization.

The DTP vaccines market size is expected to see strong growth in the next few years. It will grow to $7.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to strong late-stage pipeline and new drug approvals, increased healthcare expenditure and immunization policies to eradicate endemic diseases. Major trends in the forecast period include focusing on development of combination vaccines, investing extensively in R&D activities, using artificial intelligence (AI) in vaccine development and focusing on strategic acquisitions.

Governments worldwide are actively endorsing the development of DTP vaccines to curb the spread of the disease. Initiatives such as India's Universal Immunization Program, designed to provide recommended vaccines, including those against tuberculosis, polio, diphtheria, tetanus, and whooping cough, for all children in the country, contribute to regular vaccination drives. These efforts are anticipated to have a positive impact on market growth in the forecast period.

The rising healthcare expenditure is anticipated to drive the growth of the DTP vaccine market in the coming years. Healthcare expenditure refers to the total financial resources allocated to healthcare goods and services, which includes medical equipment, hospital services, physician services, prescription drugs, and public health initiatives. This expenditure plays a crucial role in creating an environment conducive to the development, production, distribution, and effective use of DTP vaccines. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that UK healthcare expenditure reached approximately $379 billion (£292 billion) in 2023. This represented a 5.6% nominal increase compared to 2022, significantly up from the 0.9% growth seen in the previous year. Consequently, the rise in healthcare expenditure is expected to propel the growth of the DTP vaccine market.

Prominent companies in the diphtheria, tetanus, and pertussis (DTP) vaccine market are dedicated to developing innovative vaccines such as BOOSTRIX to establish a competitive advantage. BOOSTRIX, introduced by GSK PLC, a UK-based biotechnology and pharmaceutical company, is a vaccine designed to protect adolescents (ages 10-18) and adults from diseases caused by Bordetella pertussis, diphtheria, and tetanus bacteria. As a combination vaccine, BOOSTRIX safeguards against whooping cough (pertussis), diphtheria, and tetanus. GSK plc received approval from the US Food and Drug Administration (FDA) for BOOSTRIX in October 2022, making it the first vaccine licensed specifically for use by pregnant women to shield unborn children from illness. Administered during pregnancy, it enhances the mother's antibodies, providing protection to the growing baby.

Companies within the DTP vaccines market are increasingly investing in the production of DTP combination vaccines, streamlining the immunization process against infectious diseases by reducing the need for multiple vaccination shots. Various DTP combination vaccines, such as tetravalent (DTP-HepB), pentavalent (DTP-HepB-Hib), and hexavalent (DTP-Hib-HepB-IPV), offer equivalent protection compared to individual vaccines administered separately.

In August 2022, GSK plc executed a significant acquisition by purchasing Affinivax, Inc., a US-based biotechnology company, for $2.1 billion. This strategic move reinforces GSK's commitment to building a robust portfolio of specialized drugs and vaccines. Among the acquired assets is AFX3772, a candidate for the next-generation 24-valent pneumococcal vaccine, utilizing the groundbreaking Multiple Antigen Presenting System (MAPSTM) platform technology, currently in phase II development. Affinivax, Inc. specializes in developing preventative and therapeutic vaccines using an innovative approach to vaccine technology.

Major companies operating in the DTP vaccines market include GlaxoSmithKline, Sanofi, Merck & Co Inc, Meiji Holdings Co., Ltd, Shenzhen Kangtai Biological Products, AJ Vaccines, PT Bio Farma, Bio Med, Sinergium Biotech SA, Teuto Brasileiro, Amgen, Roche, BioFabri, Sinopharm, Chongqing Zhifei, Hualan Biological Engineering Inc, Ezequiel Dias Foundation (FUNED), BioKangtai, Uniao Quimica, Valneva SE, Bharat Biotech, Bio-Manguinhos-Institute of Technology on Immunobiologicals, Connaught Laboratories Inc, Biolab Farmaceutica, Massbiologics, Beijing Tiantan Biological Products Co Ltd, Butantan Institute, C.R.I. Kasauli, Bayer, Pfizer, Abbott Laboratories, Serum Institute of India Pvt Ltd, Novartis, Wyeth-Ayerst, Dano Vaccines, Sinovac Biotech Ltd, AbbVie Inc, Apotex, GreenSignal Bio Pharma Private Limited (GSBPL), Teva Pharmaceutical Industries Ltd F. Hoffmann-La Roche AG, Boehringer Ingelheim, CanSino Biologics, Gilead Sciences, Panacea Biotec Ltd, Fiocruz, Johnson & Johnson, Walvax biotechnology, National Administration of Laboratories and Institutes of Health (ANLIS), Zentiva, Afrigen Biologics & Vaccines.

North America was the largest region in the DTP vaccines market in 2024. The regions covered in the DTP vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the DTP vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Diphtheria, Tetanus, Pertussis (DTP) vaccines are combination vaccines administered intramuscularly to safeguard children under the age of 7 from diphtheria, tetanus, and whooping cough. These vaccines play a crucial role in conferring immunity to three bacterial diseases - diphtheria, tetanus, and pertussis - all of which can be life-threatening.

The primary product categories within DTP vaccines are DTaP, TD, and Tdap. DTaP vaccines are designed to help children under seven years of age develop immunity against three potentially deadly bacterial infections, diphtheria, pertussis (whooping cough), and tetanus. The diseases covered by these vaccines include diphtheria, pertussis, and tetanus, and they are administered in various healthcare settings such as hospitals, clinics, and vaccination centers.

The DTP vaccines market research report is one of a series of new reports that provides DTP vaccines market statistics, including global market size, regional shares, competitors with a DTP vaccines market share, detailed DTP vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the DTP vaccines industry. This DTP vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The DTP vaccine market consists of sales of Daptacel, Infanrix, Kinrix, Paediarix, Pentacel, Quadracel, and Vaxelis vaccines. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.